Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
Completed
Sunovion
Phase 3
2009-04-01
This is an 18-week, double-blind, multicenter study with gradual conversion from previous
antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial
epilepsy.
Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive
Completed
Bial - Portela C S.A.
Phase 1
2008-09-01
The purpose of this study is to investigate whether multiple-dose administration of
eslicarbazepine acetate (ESL, BIA 2-093) 800 mg once-daily (QD) affects the pharmacokinetics
and tolerability of the components of a combined oral contraceptive (ethinyloestradiol and
levonorgestrel).
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
Completed
Bial - Portela C S.A.
Phase 1
2008-11-01
This purpose of this study is to measure the concentrations of two anti-epileptic drugs
(Eslicarbazepine acetate and oxcarbazepine) and their metabolites in the cerebrospinal fluid
and blood plasma of healthy subjects and also to assess how these drugs are tolerated.
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
Completed
Bial - Portela C S.A.
Phase 3
2004-07-01
The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate
once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy
in patients with refractory partial epilepsy over a 12-week maintenance period. Patients who
complete Part I may enter a 1-year open-label extension.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
